Skip to main content

Table 1 Baseline clinical characteristics

From: Coronary artery calcium score plays an important role for cardiovascular risk stratification in the statin benefit groups of asymptomatic individuals

Total = 3817 Low-intensity statin therapy (n = 931) Moderate-intensity statin therapy group
(n = 1602)
High-intensity statin therapy group
(n = 1284)
p-value
Age, year 50 ± 12 53 ± 8 58 ± 8 <0.001
Gender, male, n (%) 466 (50.1) 751 (46.9) 761 (59.3) <0.776
Hypertension, n (%) 272 (29.2) 488 (30.5) 493 (38.4) <0.001
Diabetes, n (%) 21 (0.2) 191 (11.9) 211 (16.4) <0.001
Dyslipidemia, n (%) 136 (14.6) 194 (12.1) 242 (18.8) <0.001
Familial history of CVA, n (%) 121 (13.0) 304 (19.0) 500 (38.9) 0.145
Body mass index, kg/m2 24.1 ± 3.8 24.6 ± 3.6 25.4 ± 3.0 <0.001
Waist circumference, cm 85 ± 9 87 ± 9 90 ± 9 <0.001
Systolic BP, mm Hg 120 ± 13 122 ± 13 128 ± 14 <0.001
Diastolic BP, mm Hg 120 ± 13 72 ± 9 77 ± 10 <0.001
Heart rate, beats per minute 62 ± 8 64 ± 9 64 ± 10 0.206
Smoking status, n (%) 308 (33.1) 144 (9.0) 537 (41.8) <0.001
Total cholesterol, mg/dL 138 ± 19 201 ± 32 209 ± 39 <0.001
Triglyceride, mg/dL 148 ± 16 106 ± 75 141 ± 86 <0.001
HDL-C, mg/dL 50 ± 14 54 ± 13 47 ± 10 <0.001
LDL-C, mg/dL 59 ± 11 122 ± 28 130 ± 35 <0.001
Fasting blood glucose, mg/dL 91 ± 14 98 ± 24 105 ± 28 <0.001
HbA1c, % 5.5 ± 0.4 5.7 ± 0.8 5.9 ± 0.9 <0.001
Fasting insulin, IU/L 8.8 ± 7.0 8.0 ± 5.2 9.1 ± 6.5 0.246
HOMA-IR, 1.9 ± 2.3 2.0 ± 1.6 2.4 ± 2.1 0.104
C reactive protein, mg/dL 0.11 ± 0.37 0.17 ± 0.56 0.18 ± 0.44 0.099
Ten-year, ASCVDS, % 2.1 ± 2.0 2.9 ± 1.9 12.6 ± 5.3 <0.001
CACS 2 ± 8 3 ± 2 98 ± 270 <0.001
  1. Data are expressed as means ± standard deviation
  2. CVA cerebrovascular accident, BP blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HOMA-IR homeostasis model assessment insulin resistance, CAC coronary artery calcium, ASCVD atherosclerotic cardiovascular disease